VIOLIN Logo
VO Banner
Search: for Help
About
Introduction
Statistics
VIOLIN News
Your VIOLIN
Register or Login
Submission
Tutorial
Vaccine & Components
Vaxquery
Vaxgen
VBLAST
Protegen
VirmugenDB
DNAVaxDB
CanVaxKB
Vaxjo
Vaxvec
Vevax
Huvax
Vaccine Mechanisms
Vaximmutordb
Vaxism
Vaxar
Vaccine Literature
VO-SciMiner
Litesearch
Vaxmesh
Vaxlert
Vaccine Design
Vaxign
Community Efforts
Vaccine Ontology
ICoVax 2012
ICoVax 2013
Advisory Committee
Vaccine Society
Vaxperts
VaxPub
VaxCom
VaxLaw
VaxMedia
VaxMeet
VaxFund
VaxCareer
Data Exchange
V-Utilities
VIOLINML
Help & Documents
Publications
Documents
FAQs
Links
Acknowledgements
Disclaimer
Contact Us
UMMS Logo

Vaccine Comparison

HVT-ND Newcastle disease virus DNA vaccine pCAGF encoding the F protein Newcastle Disease Virus HN Glycoprotein Subunit Vaccine rAPMV3-F (newcastle disease)
Vaccine Information Vaccine Information Vaccine Information Vaccine Information
  • Vaccine Ontology ID: VO_0004632
  • Type: Recombinant vector vaccine
  • Status: Research
  • Host Species for Licensed Use: Baboon
  • F fusion protein gene engineering:
    • Type: Recombinant vector construction
    • Description: A turkey herpesvirus vector Newcastle disease vaccine (HVT/ND) expressing the fusion gene of Newcastle disease virus (NDV) (Esaki et al., 2013).
    • Detailed Gene Information: Click Here.
  • Vector: (Esaki et al., 2013)
  • Preparation: A turkey herpesvirus vector Newcastle disease vaccine (HVT/ND) expressing the fusion gene of Newcastle disease virus (NDV) (Esaki et al., 2013).
  • Immunization Route: Intramuscular injection (i.m.)
  • Vaccine Ontology ID: VO_0004324
  • Type: DNA vaccine
  • Status: Research
  • Host Species as Laboratory Animal Model: Chicken
  • F fusion protein gene engineering:
    • Type: DNA vaccine construction
    • Description: Vector Pcaggs expressed the Newcastle disease virus Fprotein (NDV-F) (Sakaguchi et al., 1996).
    • Detailed Gene Information: Click Here.
  • Vector: Pcaggs (Sakaguchi et al., 1996)
  • Immunization Route: Intramuscular injection (i.m.)
  • Vaccine Ontology ID: VO_0011552
  • Type: Subunit vaccine
  • Status: Research
  • Antigen: Hemagglutinin-neuraminidase (HN) glycoprotein (Lee et al., 2008).
  • HN hemagglutinin-neuraminidase gene engineering:
    • Type: Recombinant protein preparation
    • Detailed Gene Information: Click Here.
  • Adjuvant: Montanide incomplete Seppic adjuvant
  • Vector: Baculovirus (Lee et al., 2008).
  • Immunization Route: Intramuscular injection (i.m.)
  • Vaccine Ontology ID: VO_0004684
  • Type: Recombinant vector vaccine
  • Status: Research
  • Host Species for Licensed Use: Baboon
  • F fusion protein gene engineering:
    • Type: Recombinant protein preparation
    • Description: Recombinant viruses, rAPMV3-F and rAPMV3-HN, were generated expressing the NDV fusion (F) and hemagglutinin-neuraminidase (HN) proteins (Kumar et al., 2011).
    • Detailed Gene Information: Click Here.
  • HN hemagglutinin-neuraminidase gene engineering:
    • Type: Recombinant vector construction
    • Description: Recombinant viruses, rAPMV3-F and rAPMV3-HN, were generated expressing the NDV fusion (F) and hemagglutinin-neuraminidase (HN) proteins (Kumar et al., 2011).
    • Detailed Gene Information: Click Here.
  • Preparation: Recombinant virus, rAPMV3-F generated expressinv the NDV fusion protein (Kumar et al., 2011).
  • Immunization Route: Intramuscular injection (i.m.)
Host Response Host Response Host Response Host Response

Chicken Response

  • Vaccination Protocol: Chickens were vaccinated by the in ovo route to 18-day-old embryos or by the subcutaneous route to 1-day-old chicks (Esaki et al., 2013).
  • Vaccine Immune Response Type: VO_0003057
  • Challenge Protocol: Challenge was conducted using a low-virulence NDV strain (genotype II; pathotype lentogenic) via the respiratory tract each week between 1 and 5 weeks of age, in order to mimic the situation in areas where virulent NDV strains do not normally exist and low-virulence strains cause mild respiratory symptoms leading to economic losses (Esaki et al., 2013).
  • Efficacy: Partial protection was observed at 3 weeks of age, when 6 out of 10 (60%) chickens were protected. Full protection was obtained at 4 and 5 weeks of age, when 9 out of 10 (90%) and 10 out of 10 (100%) chickens were protected, respectively. Finally, protection against challenge with virulent Texas GB strain at 19 weeks of age was evaluated in commercial female layer chickens vaccinated at 1 day of age with HVT/ND. All of the vaccinated chickens were protected, while all of the challenge controls succumbed to the challenge (Esaki et al., 2013).

Chicken Response

  • Vaccine Immune Response Type: VO_0000286
  • Efficacy: At 9 weeks post-injection, chickens were challenged with the velogenic NDV Sato strain. The chickens that had the antibody against NDV-F from immunization were protected from lethal NDV challenge. The DNA vaccine conferred efficient protection against the disease (Sakaguchi et al., 1996).

Chicken Response

  • Vaccination Protocol: For vaccination, chickens were inoculated intramuscularly with the Seppic-adjuvanted antigen (Lee et al., 2008).
  • Challenge Protocol: Each group of vaccinated and unvaccinated chickens was challenged with the vvNDV Kr-005/00 strain through an intraocular inoculation with an 105.5 EID50 per bird. vvNDV Kr-005/00 was the representative strain of genotype VII, which is the dominant epizootic genotype in Korea. The chickens were kept under observation for 14 days after infection (Lee et al., 2008).
  • Efficacy: A single dose of rNDHN(V) had a protective effect against mortality (p <0.01) in chickens (Lee et al., 2008).

Chicken Response

  • Vaccination Protocol: 2-week-old chickens were immunized by the oculonasal route in order to evaluate the contribution of each protein to the induction of NDV-specific neutralizing antibodies and protective immunity (Kumar et al., 2011).
  • Vaccine Immune Response Type: VO_0003057
  • Challenge Protocol: The immunized birds were challenged 21 days after vaccination with virulent NDV via the oculonasal, intramuscular, or intravenous route (Kumar et al., 2011).
  • Efficacy: With oculonasal or intramuscular challenge, all three recombinant viruses (rAPMV3, rAPMV3-F, and rAPMV3-HN) were protective, while all unvaccinated birds succumbed to death. However, with intravenous challenge, birds immunized with rAPMV3 were not protected, whereas birds immunized with rAPMV3-F alone or in combination with rAPMV3-HN were completely protected, and birds immunized with rAPMV3-HN alone were partially protected. These results indicate that the NDV F and HN proteins are independent neutralization and protective antigens, but the contribution by F is greater (Kumar et al., 2011).
References References References References
Esaki et al., 2013: Esaki M, Godoy A, Rosenberger JK, Rosenberger SC, Gardin Y, Yasuda A, Dorsey KM. Protection and antibody response caused by turkey herpesvirus vector Newcastle disease vaccine. Avian diseases. 2013; 57(4); 750-755. [PubMed: 24597117].
Sakaguchi et al., 1996: Sakaguchi M, Nakamura H, Sonoda K, Hamada F, Hirai K. Protection of chickens from Newcastle disease by vaccination with a linear plasmid DNA expressing the F protein of Newcastle disease virus. Vaccine. 1996; 14(8); 747-752. [PubMed: 8817820].
Lee et al., 2008: Lee YJ, Sung HW, Choi JG, Lee EK, Yoon H, Kim JH, Song CS. Protection of chickens from Newcastle disease with a recombinant baculovirus subunit vaccine expressing the fusion and hemagglutininneuraminidase proteins. Journal of veterinary science. 2008; 9(3); 301-308. [PubMed: 18716451].
Kumar et al., 2011: Kumar S, Nayak B, Collins PL, Samal SK. Evaluation of the Newcastle disease virus F and HN proteins in protective immunity by using a recombinant avian paramyxovirus type 3 vector in chickens. Journal of virology. 2011; 85(13); 6521-6534. [PubMed: 21525340].